Related Experiment Videos
Acute respiratory infections (ARI) in children: prospects for prevention
1Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor 48109, USA. asmonto@umich.edu
Insights
Vaccines are crucial for preventing childhood acute respiratory infections (ARI) and deaths, especially in developing nations. Developing combination vaccines and maternal immunization strategies can improve child health outcomes globally.
Area of Science:
- Pediatrics
- Infectious Diseases
- Vaccinology
Background:
- Acute respiratory infections (ARI) are a leading cause of childhood morbidity and mortality, particularly in developing countries.
- Bacterial infections often follow viral ARI, contributing to high case fatality rates.
- Current case management relies on antibiotics, highlighting the need for primary prevention through vaccines.
Framework:
- Vaccines targeting viruses like respiratory syncytial virus and parainfluenza virus can prevent initial infections.
- Vaccines against bacterial pathogens such as Haemophilus influenzae and Streptococcus pneumoniae are essential for reducing mortality.
- Maternal immunization offers a promising strategy for early-life protection in vulnerable populations.
Implementation:
- Combination vaccines are advantageous due to difficulties in accessing healthcare systems in resource-limited settings.
- Successful introduction of new vaccines requires demonstrated cost-effectiveness.
- Acceptance by policymakers is critical for widespread vaccine adoption and public health impact.
Implications:
- Vaccination strategies can significantly reduce the burden of ARI in children worldwide.
- Maternal immunization and combination vaccines represent key advancements in pediatric infectious disease prevention.
- Economic evaluation and stakeholder engagement are vital for implementing effective vaccine programs in developing regions.
Abstract:
Acute respiratory infections (ARI) are a major cause of morbidity in children worldwide, and are estimated to cause four million deaths per year, mainly in the developing world. In those countries, bacterial infection with high case fatality is common, apparently following a primary viral infection. The case management strategy has had success in controlling severe outcomes. However, its dependence on the use of antibiotics and the advantage of primary prevention support the need for vaccines. Vaccines against viruses such as respiratory syncytial and parainfluenza would prevent what is often the initial infection and vaccines against Haemophilus influenzae and S. pneumoniae the major bacterial causes of mortality. Maternal immunization may have special relevance in developing countries where protection early in life is required. The development of combination vaccines would also be especially useful, since contacts with the medical system are often difficult. The introduction and use of new vaccines in those regions will require demonstration of cost effectiveness and acceptance by policy makers.